Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults...( PHILADELPHIA March 31 /- Shire pl...)

PHILADELPHIA, March 31 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced a co-promotion agreement with GlaxoSmithKline plc (NYSE: GSK) for VYVANSE(R) (lisdexamfetamine dimesylate) capsules CII with the aim of improving recognition and treatment of ADHD in adults. This three year agreement covers the United States and will more than double the reach and frequency of the current sales effort for VYVANSE by adding over 600 sales representatives from GSK who call on specialists and primary care physicians. Shire currently has nearly 600 representatives promoting VYVANSE, primarily to pediatricians and psychiatrists.

"Shire is an established leader in developing and commercializing medicines that help patients with ADHD manage their symptoms," said Michael Cola, President of Shire's Specialty Pharmaceuticals business. "Since its launch in 2007, VYVANSE has become the fastest-growing, once-daily, prescription ADHD treatment in the United States and today has achieved nearly 12 percent of the prescription ADHD market. Increased diagnosis and treatment of adults with ADHD is a significant driver of growth in this category, and by collaborating with GSK, which has two of the most accomplished CNS and Primary Care sales teams in the industry, VYVANSE will be introduced to over 70,000 new physicians. We believe Shire, GSK and adults with ADHD will benefit from this agreement."

"GSK has been active in discovering and developing medicines to treat psychiatric disorders for decades, and neuroscience is one of the company's key therapeutic categories," said Deirdre Connelly, President, GlaxoSmithKline North American Pharmaceuticals. "Our professional sales
'/>"/>